Clinical and economic evaluation of gatifloxacin and levofloxacin

References

• Sullivan SD, Lyles A, Luce B, Griger J. AMCP guidance for submission of clinical and economic evaluation data to support formulary listing in US health plans and pharmacy benefits management organizations. I Managed Cate Phatm. 7(4), 272–282 (2001).
   Google Scholar
• Seppala H, Klaukka T, Vuopio-Varkila J et al The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. N Engl. I Med. 337,441–446 (1997).
   PubMed Web of Science ®Google Scholar
• McDonald LC, Kuehnert MJ, Tenover FC, Jarvis WR. Vancomycin-resistant enterococci outside the health-care setting: prevalence, scores, and public health implications. Emerg. Infer. Dis. 3(3), 311–317 (1997).
   Google Scholar
• Dowell SF, Schwartz B. Resistant pneumococci: protecting patients through judicious use of antibiotics. Am. Family Phys. 55(5), 1647–1658 (1997).
   PubMedGoogle Scholar
• Chen DK, McGeer A, de Azavedo JC, Low DE, Canadian Bacterial Surveillance Network. Decreased susceptibility of Streptococcus pneumordae to fluoroquinolones in Canada. N Engl. Med. 341,233–239 (1999).
   Google Scholar
• Clark JP, Langston E. Ketolides: a new class of antibacterial agents for treatment of community-acquired respiratory tract infections in a primary care setting. Mayo Clinic Proc. 78(9), 1113–1124 (2003).
   Google Scholar
• Gonzales R, Bartlett JG, Besser RE et al Principles of appropriate antibiotic use for treatment of acute respiratory tract infections in adults: background, specific aims, and methods. Ann. Intern. Med. 134 (6), 479–486 (2001).
   Google Scholar
• CareFirst BlueCross BlueShield. Drug Utilization Review, Antibiotic Utilization Patterns. August (2000).
   Google Scholar
• Ball P The quinolones: history and overview. In: The Quinolones. Third Edition. Andriole VT (Ed.). Academic Press, CA, USA 2–24 (2000).
   Google Scholar
• Aminimanizani A, Beringer P, Jelliffe R. Comparative pharmacokinetics and pharmacodynamics of the newer fluoroquinolone antibacterials. Clin. Phatmacokine. 40(3), 169–187 (2001).
   Google Scholar
• Levaquin (levofloxacin). Ord-10-McNeil, NJ, USA (2004).
   Google Scholar
• Tequin (gatifloxacin). Bristol—Myers Squibb Company, NJ, USA (2003).
   Google Scholar
• Dunbar LM, Wunderrink RG, Habib MP etal. High-dose, short-course levofloxacin for community-acquired pneumonia: a new treatment paradigm. Clin. Infect. Dis. 37,752-760 (2003). Details higher dose, shorter therapy for community-acquired pneumonia.
   Google Scholar
• Trampuz A, Laifer G, Wenk M, Rajacic Z, Zimmerli W Pharmacokinetics and pharmacodynamics of gatifloxacin against Streptococcus pneumoniae and Staphylococcus aureus in a granulocyte-rich exudate. Antimicrob. Agents Chem. 46(11), 3630–3633 (2002).
   PubMedGoogle Scholar
• Croom KF, Goa KL. Levofloxacin: a review of its use in the treatment of bacterialinfections in the United States. Drugs 63(24), 2769–2802 (2003).
   PubMed Web of Science ®Google Scholar
• Fish D, Chow A. The clinical pharmacokinetics of levofloxacin. Clin. Phatmacokinet. 32,101–119 (1997).
   PubMed Web of Science ®Google Scholar
• Hoffken G, Lode H, Wiley P. Pharmacokinetics and interaction in the bioavailability of new quinolones. Proceedings of the International Symposium on the New Quinolones. Geneva, Switzerland. (1996)
   Google Scholar
• Perry C, Balfour J, Lamb H. Gatifloxacin. Drugs 58,683–698 (1999).
   PubMed Web of Science ®Google Scholar
• Lober S, Ziege S, Rau M eta]. Pharmacokinetics of gatifloxacin and interaction with an antacid containing aluminum and magnisium. Antic-Ida-ob. Agents Chemother 43,1067–1071 (1999).
   Google Scholar
• Hypoglycemia and hyperglycemia with fluoroquinolones. Med. Letter45 (1162), 64 (2003).
   Google Scholar
• Gaijar DA, LaCreta FP, Kollia GD et al Effect of multiple-dose gatifloxacin or ciprofloxacin on glucose homeostasis and insulin production in patients with noninsulin-dependent diabetes mellitus maintained with diet and exercise. Pharmacotherapy20(6 Pt 2), S76—S86 (2000).
   Google Scholar
• Iannini PB. Cardiotoxicity of macrolides, ketolides and fluoroquinolones that prolong the QTc interval. Expert Opin. Drug Safetyl (2), 121–128 (2002).
   Google Scholar
• Hon i S, Kizu J, Kawamura M. Effects of anti-inflammatory drugs on convulsant activity of quinolones: a comparative study of drug interaction between quinolones and anti-inflammatory drugs. I Infect. Chemother. 9(4), 314–320 ( 2003).
   Google Scholar
• Gold L, Igra H. Levofloxacin-induced tendon rupture: a case report and review of the literature. J. Am. Board Fain. Prod. 16(5), 458–460 (2003).
   Google Scholar
• Hyatt J, Mainno P, Zimmer G etal. The importance of phamacokinetid pharmacodynamic surrogate markers to outcome: focus on antibacterial agents. Clin. Pharmakinet 28,143–160 (1995).
   Google Scholar
• Saravolatz LD, Leggert J. Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones. Clin. Infect. Dis. 37,1210-1215 (2003).
   Google Scholar
• •Provides a good clinical overview of new fluoroquinolones.
   Google Scholar
• Piddock LJV, Johnson M, Ricci V, Hill SL. Activities of new fluoroquinolones against fluoroquinolone-resistant pathogens of the lower respiratory tract. Antimicrob. Agents Chemother. 42(11), 2956–2960 (1998).
   PubMed Web of Science ®Google Scholar
• Jones RN, Rubino CM, Bhavnani SM, Ambrose PG. Worldwide antimicrobial susceptibility patterns and pharmacodynamic comparisons of gatifloxacin and levofloxacin against streptococcus pneumoniae: report from the antimicrobial resistance rate epidemiology study team. Antimicrob. Agents Chemother. 47(1), 292–296 (2003).
   PubMedGoogle Scholar
• Lode H, Allewelt M. Role of newer fluoroquinolones in lower respiratory tract infections. J. Antimicrob. Chemother. 50, 151–154 (2002).
   PubMed Web of Science ®Google Scholar
• Tarshis GA, Miskin BM, Jones TM eta]. Once-daily oral gatifloxacin versus oral levofloxacin in treatment of uncomplicated skin and soft tissue infections: double-blind, multicenter, randomized study. Antimicrob. Agents Chemother. 45 (8), 2358–2362 (2001).
   Google Scholar
• Ritchie DE Cost and quality considerations in antibiotic formulary management. Mann. Prat. Manag. Q. 16(2), 4–8 (1996).
   Google Scholar
• Enzweiler KA, Bosso JA, White RL. A novel method of estimating cost of therapy by using patient population characteristics: analysis of fluoroquinolones in various populations with different distributions of renal function. Pharmacotherapy23(7), 925–932 (2003).
   PubMedGoogle Scholar